Quick Answer
Aclaris Therapeutics, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $7.83 million for the year ending 2025.
- Aclaris Therapeutics, Inc. showed a decrease of -58.2% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Aclaris Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2017: $684.0 thousand | Q4 2017: $999.0 thousand | Q1 2018: $1.12 million | Q2 2018: $3.68 million | Q3 2018: $1.12 million | Q4 2018: $3.67 million | Q1 2019: $1.26 million | Q2 2019: $886.0 thousand | Q3 2019: $983.0 thousand | Q1 2020: $1.41 million | Q2 2020: $2.05 million | Q3 2020: $1.45 million | Q1 2021: $1.78 million | Q2 2021: $1.82 million | Q3 2021: $1.66 million | Q1 2022: $1.45 million | Q2 2022: $1.53 million | Q3 2022: $19.02 million | Q1 2023: $2.53 million | Q2 2023: $1.87 million | Q3 2023: $9.28 million | Q1 2024: $2.40 million | Q2 2024: $2.77 million | Q3 2024: $4.35 million | Q1 2025: $1.46 million | Q2 2025: $1.78 million | Q3 2025: $3.30 million.
- Over the full 9 years of available data (2017 to 2025), Aclaris Therapeutics, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 365.0%.
- Historical annual values: Fiscal year 2025: $7.83 million | Fiscal year 2024: $18.72 million | Fiscal year 2023: $31.25 million | Fiscal year 2022: $29.75 million | Fiscal year 2021: $6.76 million | Fiscal year 2020: $6.48 million | Fiscal year 2019: $4.23 million | Fiscal year 2018: $6.15 million | Fiscal year 2017: $1.68 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: